# Ovarian Cancer Aspirin has a real but more modest signal in **ovarian cancer**. The strongest evidence is in **prevention**, not treatment. The effect size is smaller than in colorectal cancer and probably smaller than in endometrial cancer. It also varies by histotype and use pattern. ### Overview Ovarian cancer is one of the most lethal gynaecological cancers because it is often diagnosed late. That makes any credible prevention signal worth paying attention to. Aspirin has one. But the case needs honest framing. The benefit looks **modest**, more relevant in **non-mucinous** and **high-grade serous** disease, and still weak on post-diagnosis trial evidence. [Read the pooled analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801817) ### Key human data #### Prevention and risk reduction The key human signal comes from pooled observational data. * **Pooled analysis of 17 studies:** Frequent aspirin use was associated with an overall **13% lower ovarian-cancer risk**, with an odds ratio of **0.87**. [Read the pooled analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801817) * **Case-control studies:** The pooled odds ratio was **0.84**, which is a somewhat stronger prevention signal than the cohort estimate. [Read the summary](https://cancerworld.net/frequent-aspirin-ovarian-cancer-risk-reduction/) * **Cohort studies:** The pooled hazard ratio was about **0.90**. That still points in the same direction, but with a smaller effect size. [Read the summary](https://cancerworld.net/frequent-aspirin-ovarian-cancer-risk-reduction/) * **Histotype-specific signal:** The best signal appears in **high-grade serous** and other **non-mucinous** cancers. The mucinous subtype looks less responsive. [Read the FORCE summary](https://www.facingourrisk.org/XRAY/aspirin-to-prevent-ovarian-cancer) * **Genetic risk:** In the 2023 pooled analysis, the association was **not materially changed by polygenic risk score**. That suggests the aspirin signal may still matter even when inherited risk is higher. [Read the pooled analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801817) * **Low-dose aspirin, 2024:** A newer analysis linked low-dose aspirin with lower ovarian-cancer risk, especially in **nulliparous women** and women **without cardiovascular disease history**. Women with prior cardiovascular disease did not show the same benefit. [Read the Nature record](https://www.nature.com/articles/s41416-024-02609-7) This is meaningful. It is just not a large effect. #### Post-diagnosis survival Post-diagnosis data is sparse. One Australian cohort linked regular low-dose aspirin use with better survival in **late-stage ovarian cancer**. [Read the ABC summary](https://www.abc.net.au/news/health/2023-02-07/aspirin-may-improve-ovarian-cancer-survival-rate-in-women/101939492) That result is interesting, but it is not enough to change practice. It remains a single supportive dataset rather than a replicated oncology trial signal. ### Mechanistic relevance #### COX-2 and inflammatory signalling Ovarian tumours often show increased **COX-2** expression. Higher inflammatory signalling can support tumour survival, immune escape, and resistance to platinum therapy. Aspirin fits this biology at least in principle. [Read the gynaecological review](https://journals.sagepub.com/doi/10.1177/1745506520961710) #### Platelet and TXA2 biology Ovarian cancer also has strong platelet relevance. This disease carries a high burden of cancer-associated thrombosis and platelet activation. That matters because platelets can shield tumour cells and support metastatic spread across the peritoneum. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10342211/) Aspirin may matter here through platelet **COX-1** inhibition and **TXA2** suppression. For the broader mechanism, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). #### Energy metabolism and hypoxia More speculative work suggests aspirin may alter **glutamine use** and broader energy metabolism in hypoxic ovarian-cancer cells. This is still early-stage biology, not clinical evidence. [Read the Scientific Reports paper](https://www.nature.com/articles/s41598-026-42753-z) #### PIK3CA relevance **PIK3CA** mutations are less common here than in endometrial cancer, but they still matter. Reported rates are roughly **10% to 15%**, with higher relevance in endometrioid ovarian tumours. [Read the AACR pan-cancer analysis](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf) That is not yet a validated aspirin biomarker in ovarian cancer. It is simply a plausible biology overlap. ### Clinical positioning | Setting | Evidence | Position | | ---------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------- | | **Prevention with frequent aspirin use** | Pooled **13%** risk reduction across 17 studies. [Read the pooled analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801817) | Modest but real | | **High-grade serous and non-mucinous disease** | Stronger histotype-specific prevention signal. [Read the FORCE summary](https://www.facingourrisk.org/XRAY/aspirin-to-prevent-ovarian-cancer) | Best-supported subgroup | | **Mucinous ovarian cancer** | No convincing signal. [Read the pooled analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801817) | Not supported | | **Nulliparous women** | Stronger low-dose prevention signal in one newer study. [Read the Nature record](https://www.nature.com/articles/s41416-024-02609-7) | Possible enriched subgroup | | **Women with cardiovascular disease history** | No clear benefit in one low-dose analysis. [Read the Nature record](https://www.nature.com/articles/s41416-024-02609-7) | Weak or absent signal | | **Post-diagnosis use in late-stage disease** | Single cohort suggests better survival. [Read the ABC summary](https://www.abc.net.au/news/health/2023-02-07/aspirin-may-improve-ovarian-cancer-survival-rate-in-women/101939492) | Hypothesis-supporting only | ### Honest evidence assessment This page should stay more restrained than the endometrial page. The prevention signal is consistent enough to take seriously. But the effect size is still only around **10% to 15%** in most summaries. There is no Phase 3 adjuvant trial. There is no biomarker-validated subgroup equivalent to **PIK3CA-selected** colorectal cancer. Post-diagnosis evidence is still thin. [Read the review record](https://pubmed.ncbi.nlm.nih.gov/38965997/) So the current clinical use case is mostly a **prevention discussion**, not an adjuvant-treatment conclusion. ### Practical interpretation The most useful questions for patients are: 1. What was the tumour **histotype** — high-grade serous, endometrioid, mucinous, or clear cell? 2. Is the main question **prevention** before diagnosis, or aspirin use **after diagnosis**? 3. Is there a history of **BRCA-related** or other inherited ovarian-cancer risk? 4. Is the patient **nulliparous**, or is there a history of **cardiovascular disease** that might change the balance? 5. Has tumour profiling shown anything relevant, such as **PIK3CA** alteration? The signal here is worth knowing. It is just not strong enough to overstate. ### References * *JAMA Network Open* 2023 — pooled analysis of 17 studies and a **13%** lower ovarian-cancer risk. [Read the pooled analysis](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801817) * CancerWorld summary — cohort and case-control effect sizes from pooled ovarian-cancer data. [Read the summary](https://cancerworld.net/frequent-aspirin-ovarian-cancer-risk-reduction/) * *British Journal of Cancer* 2024 — low-dose aspirin, nulliparity, and cardiovascular-disease subgroup findings. [Read the Nature record](https://www.nature.com/articles/s41416-024-02609-7) * FORCE XRAY summary — histotype-specific reduction in high-grade serous ovarian cancer. [Read the summary](https://www.facingourrisk.org/XRAY/aspirin-to-prevent-ovarian-cancer) * Australian cohort coverage — low-dose aspirin and late-stage ovarian-cancer survival. [Read the ABC summary](https://www.abc.net.au/news/health/2023-02-07/aspirin-may-improve-ovarian-cancer-survival-rate-in-women/101939492) * Review of platelet activation and cancer-associated thrombosis in ovarian and other solid tumours. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10342211/) * Yang et al., *Nature* 2025 — platelet **TXA2**, immune escape, and metastatic spread. [Read the University of Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) * *Scientific Reports* 2026 — aspirin and glutamine-energy metabolism in hypoxic ovarian-cancer cells. [Read the paper](https://www.nature.com/articles/s41598-026-42753-z) * AACR pan-cancer analysis — **PIK3CA** frequency context. [Read the analysis](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/ovarian-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.